Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News SQZ Biotechnologies Company SQZ

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide...


Recent & Breaking News (NYSE:SQZ)

SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates

Business Wire 11 days ago

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation

Business Wire July 12, 2022

SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

Business Wire July 11, 2022

SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Business Wire June 21, 2022

SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs

Business Wire June 16, 2022

SQZ Biotechnologies to Present at Jefferies Healthcare Conference

Business Wire June 1, 2022

SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

Business Wire May 31, 2022

SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

Business Wire May 18, 2022

SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates

Business Wire May 10, 2022

SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022

Business Wire May 5, 2022

SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research

Business Wire May 5, 2022

SQZ Biotechnologies to Present at Upcoming Investor Conferences

Business Wire May 3, 2022

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Business Wire April 27, 2022

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

Business Wire April 11, 2022

SQZ Biotechnologies to Present at Upcoming Investor Conferences

Business Wire April 6, 2022

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform's Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Business Wire April 4, 2022

SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson's Disease

Business Wire March 21, 2022

SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates

Business Wire March 16, 2022

SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting

Business Wire March 8, 2022

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC's Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation

Business Wire February 1, 2022